Aprocitentan for treating resistant hypertension [TSID10395]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 13 February 2026Expected publication date: 21 May 2026
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC